Geode Capital Management
ADMA icon

Geode Capital Management’s ADMA Biologics ADMA Stock Holding History

Geode Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.5M Sell
5,824,116
-6,825
-0.1% -$108K ﹤0.01% 1469
2025
Q4 		$106M Buy
5,830,941
+17,203
+0.3% +$290K 0.01% 1037
2025
Q3 		$85.2M Sell
5,813,738
-99,383
-2% -$1.7M 0.01% 1175
2025
Q2 		$108M Buy
5,913,121
+245,309
+4% +$5M 0.01% 984
2025
Q1 		$112M Buy
5,667,812
+235,428
+4% +$4.07M 0.01% 917
2024
Q4 		$93.2M Buy
5,432,384
+50,399
+0.9% +$948K 0.01% 1049
2024
Q3 		$108M Buy
5,381,985
+137,989
+3% +$2.15M 0.01% 950
2024
Q2 		$58.6M Buy
5,243,996
+437,890
+9% +$3.67M 0.01% 1253
2024
Q1 		$31.7M Buy
4,806,106
+158,169
+3% +$865K ﹤0.01% 1648
2023
Q4 		$21M Buy
4,647,937
+296,324
+7% +$1.1M ﹤0.01% 1890
2023
Q3 		$15.6M Buy
4,351,613
+178,647
+4% +$688K ﹤0.01% 1982
2023
Q2 		$15.4M Buy
4,172,966
+126,716
+3% +$470K ﹤0.01% 2034
2023
Q1 		$13.4M Buy
4,046,250
+659,398
+19% +$2.28M ﹤0.01% 2077
2022
Q4 		$13.1M Buy
3,386,852
+100,723
+3% +$311K ﹤0.01% 2067
2022
Q3 		$7.99M Buy
3,286,129
+94,001
+3% +$226K ﹤0.01% 2396
2022
Q2 		$6.32M Buy
3,192,128
+1,474,049
+86% +$2.9M ﹤0.01% 2570
2022
Q1 		$3.14M Buy
1,718,079
+304,554
+22% +$475K ﹤0.01% 3035
2021
Q4 		$1.99M Buy
1,413,525
+100,431
+8% +$132K ﹤0.01% 3359
2021
Q3 		$1.48M Buy
1,313,094
+259,767
+25% +$364K ﹤0.01% 3492
2021
Q2 		$1.69M Sell
1,053,327
-304,822
-22% -$536K ﹤0.01% 3340
2021
Q1 		$2.39M Buy
1,358,149
+349,412
+35% +$800K ﹤0.01% 3166
2020
Q4 		$1.97M Buy
1,008,737
+29,592
+3% +$62.2K ﹤0.01% 3093
2020
Q3 		$2.34M Sell
979,145
-109,850
-10% -$301K ﹤0.01% 2793
2020
Q2 		$3.19M Sell
1,088,995
-44,989
-4% -$129K ﹤0.01% 2578
2020
Q1 		$3.27M Buy
1,133,984
+417,376
+58% +$1.44M ﹤0.01% 2397
2019
Q4 		$2.87M Buy
716,608
+94,114
+15% +$410K ﹤0.01% 2781
2019
Q3 		$2.77M Buy
622,494
+184,934
+42% +$773K ﹤0.01% 2742
2019
Q2 		$1.69M Buy
437,560
+115,377
+36% +$509K ﹤0.01% 3047
2019
Q1 		$1.22M Buy
322,183
+45,253
+16% +$160K ﹤0.01% 3078
2018
Q4 		$661K Buy
276,930
+34,818
+14% +$172K ﹤0.01% 3264
2018
Q3 		$1.5M Buy
242,112
+41,002
+20% +$236K ﹤0.01% 3038
2018
Q2 		$907K Buy
201,110
+89,110
+80% +$444K ﹤0.01% 3224
2018
Q1 		$515K Hold
112,000
– – ﹤0.01% 3384
2017
Q4 		$359K Buy
112,000
+90,474
+420% +$253K ﹤0.01% 3480
2017
Q3 		$66K Hold
21,526
– – ﹤0.01% 3896
2017
Q2 		$82K Sell
21,526
-2,032
-9% -$8.16K ﹤0.01% 3877
2017
Q1 		$114K Buy
23,558
+276
+1% +$1.36K ﹤0.01% 3801
2016
Q4 		$119K Buy
23,282
+184
+0.8% +$1.06K ﹤0.01% 3750
2016
Q3 		$167K Buy
+23,098
New +$147K ﹤0.01% 3658

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Geode Capital Management's ADMA Position: Q1 2026 in Review

Geode Capital Management reduced its ADMA Biologics (ADMA) stake by 0.12% in Q1 2026, selling an estimated $108K and leaving 5,824,116 shares worth $52.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Geode Capital Management first reported a position in ADMA in Q3 2016 and has held it in 39 quarters since. The position peaked at $112M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Geode Capital Management held 5,824,116 shares of ADMA Biologics worth $52.5M as of Q1 2026.
  • Geode Capital Management sold 6,825 ADMA Biologics shares in Q1 2026, an estimated $108K.
  • ADMA Biologics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1469 holding.
  • Geode Capital Management first reported a position in ADMA Biologics in Q3 2016 and has held it in 39 quarters since.
  • Geode Capital Management's ADMA Biologics position peaked at $112M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.